A Phase II, trial of CRB-4001 in patients with Non-alcoholic steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2018
Price : $35 *
At a glance
- Drugs CRB-4001 (Primary)
- Indications Fibrosis
- Focus Proof of concept; Therapeutic Use
- 08 Nov 2018 According to a Corbus Pharmaceuticals media release, Dr. Kunos plans to coordinate this proof-of-concept clinical study at the NIH, following the completion of a phase 1 study by Corbus (299990).
- 26 Oct 2018 New trial record
- 18 Oct 2018 According to a Corbus Pharmaceuticals media release, this study will be funded by National Institutes of Health (NIH).